Reputation
-
‘Tell ’em they’re dreaming’
- Wed Apr 29
PBAC is pushing on, recommending new therapies with big price cuts and strict patient caps, ignoring the reality of the New World Order.
Read more -
ABC targets Takeda’s ADHD spend
- Wed Apr 22
The company’s very modest spend on HCPs and patients was in the spotlight, Dr Norman Swan suggesting Takeda got “a very good return on its investment”.
Read more -
Oops, did we forget to invite you?
- Mon Apr 20
Seven months after PBAC snubbed companies at a public meeting to discuss their products, its kiss-and-makeup meeting helped mend the rift.
Read more -
Lilly and Novo take GLP-1 fight to MA
- Fri Apr 10
In the ongoing fight for private market weight-loss territory, both companies paid a hefty price after failing to resolve their differences.
Read more -
PBAC tackles obesity one nibble at a time
- Wed Mar 18
May be merit in broader funding but unlikely sponsors will agree on price, PBAC advises Butler, saying it would have to be outside the PBS.
Read more -
Aussies, CEOs make TIME100 Health List
- Mon Feb 16
A Hollywood superstar and eSafety chief land spots on the prestigious 2026 list, recognised among pharma CEOS for their influence on global wellbeing.
Read more -
Why ‘Cheaper Medicines’ doesn’t pass the pub test
- Fri Feb 6
Government moves to make essential and lifestyle products cheaper doesn’t pass the pub test when it comes to timely access to medicines.
Read more -
Medicines Australia snubbed – for a bank?
- Mon Feb 2
The Pharmacy Guild has an impressive line-up again for a key event at APP26, with one significant omission and intriguing new addition.
Read more